PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Both companies show declining cash positions (-10.40% vs TRAW's -25.31%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Below half of TRAW's -25.31%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of TRAW's 2.81%. David Dodd sees a leaner approach to short-term items.
-10.80%
Below half of TRAW's -24.43%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.91%
Similar yoy growth to TRAW's -10.00%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Less than half of TRAW's 19700.00%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-8.44%
Below half of TRAW's 1781.82%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Below half of TRAW's -23.63%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Less than half of TRAW's 123.02%. David Dodd sees fewer expansions in other current obligations.
-12.74%
1.25-1.5x TRAW's -9.82%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Less than half of TRAW's -94.09%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Less than half of TRAW's -76.92%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
Below half TRAW's 3.31%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
Below half TRAW's 118.97%. Michael Burry sees potential underperformance in building shareholder capital.
-10.73%
Below half TRAW's -23.63%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
10.43%
Less than half of TRAW's 25.31%. David Dodd sees better deleveraging or stronger cash buildup than competitor.